Oncodesign has entered into its second deal of 2012, this time a 4-year strategic research collaboration with Sanofi, potentially worth up to €130 M (US$167 M), to apply its Nanocyclix® medicinal chemistry technology and research platform in multiple Sanofi kinase programmes. In January, Oncodesign formed a Parkinson’s disease drug discovery collaboration with Ipsen, which is also based on the Nanocyclix platform. A key component of Sanofi’s R&D strategy is the pursuit of partnerships with industry and academia.